

CCS/CAIC/CANCARE Optimal Care of the Post-cardiac Arrest Patient Clinical Practice Update Panel Member Disclosures April, 2024

The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Updated March 8, 2023.

Affilations with commercial organizations or clinical trials within the previous two years that may have a direct or indirect connection to the content of this statement are disclosed here.				
Members	Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
Name				
Sean van Diepen	None	None	None	None
Michel Le May	None	None	None	None
Adriana Luk	None	None	None	None
Erin Rayner-Hartley	None	None	None	None
Janek Senaratne	None	Janssen, Novartis, Idorsia	None	None
Juan Russo	None	None	None	None
Maude Peretz-Larochelle	None	None	None	None
Michael Goldfarb	None	None	None	None
Rebecca Mathew	None	None	None	None
Chris Overgaard	Boston Scientific	None	None	None
Christopher Fordyce	Bayer, Novo Nordisk, Boehringer Ingelheim, Sanofi, Novartis, New Amsterdam, HLS Therapeutics	Novartis, Amgen, Novo Nordisk	None	None
Craig Ainsworth	None	None	None	None
Emilie Belley-Côté	Trimedic Therapeutics Inc.	Atricure	None	None
Graham Wong	Boehringer Ingelheim, Novartis, Sanofi	None	None	None
Gregory Schnell	None	None	None	None
Julie Kromm	None	Marinus Pharmaceuticals - RAISE trail (Ganaxolone for seizures)	None	None
Patricia Alfaro	None	None	None	None